1. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Issue 10 (October 2017) Authors: Yazici, Y.; McAlindon, T.E.; Fleischmann, R.; Gibofsky, A.; Lane, N.E.; Kivitz, A.J.; Skrepnik, N.; Armas, E.; Swearingen, C.J.; DiFrancesco, A.; Tambiah, J.R.S.; Hood, J.; Hochberg, M.C. Journal: Osteoarthritis and cartilage Issue: Volume 25:Issue 10(2017) Page Start: 1598 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0184 Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. (15th July 2016) Authors: Lee, E.B.; Daskalakis, N.; Xu, C.; Paccaly, A.; Miller, B.; Fleischmann, R.; Bodrug, I.; Kivitz, A. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 960 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AB0240 DAS28(CRP) <3.2 Achieved with or without A TNF Inhibitor: Differences in Radiographic, Clinical, and Biomarker Outcomes between Placebo + MTX and Golimumab + MTX Treatment among Mtx-NaÏVe Patients with Rheumatoid Arthritis. (10th June 2014) Authors: Karpouzas, G.A.; Emery, P.; Fleischmann, R.; Xu, S.; Hsia, E.C. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 883 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AB0258 Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib. (12th June 2018) Authors: de Vlam, K.; Fautrel, B.; van de Laar, M.; Kirkham, B.W.; Alten, R.; Beneden, K.V.; de Leonardis, F.; Lopez-Romero, P.; Gaich, C.; Quebe, A.; Cardoso, A.; Fleischmann, R.; Emery, P. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1310 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. AB0274 Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titre on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab: 2-Year Results from the Ample Trial. (9th June 2015) Authors: Sokolove, J.; Schiff, M.; Fleischmann, R.; Weinblatt, M.E.; Connolly, S.E.; Johnsen, A.; Zhu, J.; Maldonado, M.A.; Patel, S.; Robinson, W.H. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 983 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. AB0284 Long term safety of iv golimumab and comparisons with sc golimumab in rheumatologic conditions: results from the 120-day safety report of go-further trial. (23rd January 2014) Authors: Westhovens, R.; Bingham, C. O.; Weinblatt, M.; Fleischmann, R.; Keystone, E.; Hsia, E. C.; Hsu, B.; Kim, L.; Mudivarthy, S.; Mack, M.; Goldstein, N.; Braun, J.; Kavanaugh, A.; Mendelsohn, A.; Kay, J. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A873 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. AB0287 Efficacy of etanercept (etn) plus methotrexate (mtx) vs. disease-modifying anti-rheumatic drug (dmard) combinations with mtx in established rheumatoid arthritis (ra): duration of disease and disease severity vs. outcomes. (23rd January 2014) Authors: Fleischmann, R.; Koenig, A. S.; Szumski, A.; Nab, H.; Marshall, L.; Bananis, E. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A874 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. AB0289 EFFICACY, SAFETY AND IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARING PF-06410293 (ADL-PF), AN ADALIMUMAB (ADL) BIOSIMILAR, AND REFERENCE ADL: RESULTS FROM WEEK 26–52 OF A DOUBLE-BLIND, RANDOMISED PHASE 3 STUDY INCLUDING PATIENTS WHO SWITCHED FROM ADL-PF TO REFERENCE ADL AT WEEK 26. (2nd June 2020) Authors: Fleischmann, R.; Alvarez, D.; Bock, A.; Cronenberger, C.; Vranic, I.; Zhang, W.; Alten, R. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. AB0323 Weekly subcutaneous abatacept confers comparable onset of treatment response and magnitude of efficacy improvement over 6 months when administered with or without an intravenous abatacept loading dose. (23rd January 2014) Authors: Schiff, M.; Alten, R.; Weinblatt, M.; Nash, P.; Fleischmann, R.; Durez, P.; Kaine, J.; Delaet, I.; Kelly, S.; Maldonado, M.; Patel, S.; Genovese, M. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A886 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. AB0398 Efficacy of Adalimumab and Tofacitinib in Rheumatoid Arthritis: Post-Hoc Analyses from A Phase 3 Study. (15th July 2016) Authors: van Vollenhoven, R.; Cohen, S.; Mendelsohn, A.; Bananis, E.; Fan, H.; Takiya, L.; Fleischmann, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 1042 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗